One the world's largest manufacturers of prescription generic drugs. Relocated its legal home from the USA to the Netherlands in 2015, presumably for tax reasons.
In August 2017, Mylan agreed to a $465 million settlement in a whistleblower lawsuit. The U.S. Justice Department and several states claimed the company overcharged Medicaid for EpiPens. As part of the settlement, Mylan did not have to admit any wrongdoing. The settlement came as Mylan faced growing complaints about skyrocketing price hikes for EpiPens. Between 2007 and 2016, Mylan increased the price of a two-pack of EpiPens from less than $100 to more than $600.
[Source 2017][More on Governance]
This company received a score of 20.2/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2016][More on Sustainability Reporting]
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
[Source 2016][More on Governance]
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
[Source 2016][More on Human Rights]
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
|Company Structure||Public company|
|Revenue||US$7.7 billion in 2014|
|# Employees||30,000 in 2015|
|Subsidiaries||Alphapharm Pty Ltd
- Meda Pharmaceuticals Pty Ltd
Products / BrandsMylan Australia
Dermeze Skin Care
Dermeze Bodywash/Shower Gel
Dymadon Pain Relief
Gastro-Stop Digestive Care
Irish Moss Cold & Flu
Tums Digestive Care
Waxsol Eye & Ear Care
Zantac Digestive Care